Change of the host immune response during the early phase of interferon therapy correlates with its long-term efficacy for chronic hepatitis C

Hepatology Research

Volumn 19, Issue 2, 2001, Pages 131-143

  Momosaka, Yasuhiro ^a   Yamada, Shinwa ^b   Harada, Yuji ^a   Mine, Shinichiro ^a   Tsuchiya, Yoshihiro ^c   Okubo, Hideo ^c   Eto, Sumiya ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c KITAKYUSHU MUNICIPAL MEDICAL CENTER   (Japan)

Author keywords

E selectin; Intercellular adhesion molecule 1; Interleukin 2 receptor; Vascular cell adhesion molecule 1

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; BETA INTERFERON; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; INTERCELLULAR ADHESION MOLECULE 1; INTERFERON; INTERLEUKIN 2 RECEPTOR; RECOMBINANT ALPHA2A INTERFERON; RECOMBINANT ALPHA2B INTERFERON; VASCULAR CELL ADHESION MOLECULE 1;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HEPATITIS C; HOST; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; INFLAMMATION; LONG TERM CARE; MALE; PARAMETER; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

EID: 0035152232     PISSN: 13866346     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1386-6346(00)00094-2     Document Type: Article

References (38)

1. Chronic hepatitis C and interferon alfa therapy: Predictors of long term response
2. Predictive factors for beneficial response to interferon-alfa therapy in chronic hepatitis C
3. Predictors of sustained response, relapse and no response in patients with chronic hepatitis C treated with interferon-alpha
4. Efficacy of interferon alfa therapy in chronic hepatitis C patients depends primarily on hepatitis C virus RNA level
5. Classification of hepatitis C virus into two major groups in serologic activity: Correlation with response to interferon
6. Genotypes and titers of hepatitis C virus for predicting response to interferon in patients with chronic hepatitis C
7. Predicting interferon therapy efficacy from hepatitis C virus genotype and RNA titer
8. Factors predictive of response to interferon-alpha therapy in hepatitis C virus infection
9. Diagnosis of type C chronic hepatitis using PCR technology
10. Titration and genotyping of hepatitis C virus RNA in chronic hepatitis C patients treated with interferon
11. Alpha interferon treatment of chronic hepatitis C
12. Clinicopathological assessment of hepatitis C virus infection in parenteral drug abuser
13. Hepatitis C virus (HCV) genotype, tissue HCV antigens, hepatocellular expression of HLA-A,B,C, and intercellular adhesion-1 molecules. Clues to pathogenesis of hepatocellular damage and response to interferon with chronic hepatitis C
14. Intrahepatic hepatitis C virus-specific cytotoxic T lymphocyte activity and response to interferon alfa therapy in chronic hepatitis C
15. Possible association between HLA antigens and the response to interferon in Japanese patients with chronic hepatitis C
16. Interleukin 2 and its receptors: Recent advances and new immunological functions
17. Serum interleukin 2 and soluble interleukin 2 receptor in chronic active hepatitis C: Effect of interferon therapy
18. Prediction of sustained response to interferon alpha therapy with serum soluble interleukin 2 receptor levels in patients with chronic hepatitis C
19. Elevation of serum soluble interleukin-2 receptor levels in patients with hepatitis C virus infection
20. Immunoregulatory cytokines in chronic hepatitis C virus infection: Pre- and posttreatment with interferon alfa
21. Lymphocyte interactions with endothelial cells
22. Intercellular adhesion molecule-1 expression on the hepatocyte membrane of patients with chronic hepatitis B and C
23. Soluble intercellular adhesion molecule-1 in serum in chronic hepatitis B and C
24. Serum intercellular adhesion molecule-1 levels in chronic hepatitis C: Association with disease activity and response to interferon alpha
25. The nomenclature of chronic active hepatitis: An obituary
26. Detection of circulating intercellular adhesion molecule-1 in chronic liver diseases
27. Intercellular adhesion molecule-1 concentration in sera of patients with acute and chronic liver disease: Relationship to disease activity and cirrhosis
28. Circulating soluble intercellular adhesion molecule-1 in type C viral hepatitis
29. Circulating intercellular adhesion molecule-1 (ICAM-1) in autoimmune liver disease and evidence for the production of ICAM-1 by cytokine-stimulated hepatocytes
30. Inflammatory cytokines up-regulate intercellular adhesion molecule-1 expression on primary cultured mouse hepatocytes and T-lymphocyte adhesion
31. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro
32. Down-regulation of intercellular adhesion molecule 1 on hepatocytes in viral chronic hepatitis treated with interferon alfa-2b
33. Serum levels of soluble intercellular adhesion molecule 1 (sICAM-1) as a potential marker of disease activity and remission in patients with chronic hepatitis C
34. Soluble E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in primary biliary cirrhosis
35. Serum soluble vascular-cell adhesion molecule-1 (VCAM-1) in patients with acute and chronic liver diseases
36. Increased levels of soluble adhesion molecules in the serum of patients with hepatitis C
37. Serum levels of soluble intercellular adhesion molecule-1 and soluble vascular cell adhesion molecule-1 in liver disease, and their changes by treatment with interferon
38. Serum levels of soluble vascular cellular adhesion molecule-1 (VCAM-1) during treatment with interferon alpha (IFN-α) in chronic hepatitis C